Alpha 2.0
Login Register
» Articles » PMID: 15801931

Measuring Bronchodilation in COPD Clinical Trials

Overview
Journal Br J Clin Pharmacol
Specialty Pharmacology
Date 2005 Apr 2
PMID 15801931
Citations 45
Authors
Z L Borrill
C M Houghton
A A Woodcock
J Vestbo
D Singh
Affiliations
Soon will be listed here.
Abstract

Aims: The aim of this study was to compare the variability and sensitivity of impulse oscillometry (R5, X5 and RF), plethysmography (Raw and sGaw) and spirometry (FEV1, FVC and MMEF) in order to determine the most powerful technique for assessing bronchodilation in COPD clinical trials.

Methods: Twenty-four patients with COPD had impulse oscillometry, plethysmography and spirometry measured twice 30 mins apart, to determine variability. Then ascending doses of salbutamol (20, 50, 100, 200, 400 and 800 microg) were given and the same measurements made after each dose. Significant changes greater than variability were determined for each performed measurement (expressed as mean percentage improvement with 95% CI).

Results: Significant effects (P < 0.05) were detected after 20 microg by X5 (18.5% CI 9.8-27.2) RF (11.1% CI 7.2-15.0) and sGaw (21.5% CI 10.1-32.9), and after 50 microg by R5 (16.7% CI 10.8-22.5) and Raw (19.7% CI 13.0-26.4). FEV1 was less sensitive, detecting significant bronchodilation at 100 microg (10.2% CI 7.4-12.9).

Conclusions: We conclude that impulse oscillometry and plethysmography should be considered the preferred techniques for measuring bronchodilation in COPD clinical trials.

Citing Articles

Clinical characterization and outcomes of impulse oscillometry-defined bronchodilator response: an ECOPD cohort-based study.

Lu L, Wu F, Peng J, Wu X, Hou X, Zheng Y Respir Res. 2024; 25(1):149.

PMID: 38555433 PMC: 10981824. DOI: 10.1186/s12931-024-02765-7.

Respiratory Oscillometry and Functional Performance in Different COPD Phenotypes.

Teixeira E, Ribeiro C, Lopes A, de Melo P Int J Chron Obstruct Pulmon Dis. 2024; 19:667-682.

PMID: 38464561 PMC: 10924760. DOI: 10.2147/COPD.S446085.

Short-term effect of particulate matter on lung function and impulse oscillometry system (IOS) parameters of chronic obstructive pulmonary disease (COPD) in Beijing, China.

Zhu R, Nie X, Liu X, Zhang Y, Chen J, Liu X BMC Public Health. 2023; 23(1):1417.

PMID: 37488590 PMC: 10367330. DOI: 10.1186/s12889-023-16308-0.

Response to Bronchodilators Administered via Different Nebulizers in Patients With COPD Exacerbation.

Cushen B, Alsaid A, Greene G, Costello R Respir Care. 2023; 68(11):1532-1539.

PMID: 37280080 PMC: 10589110. DOI: 10.4187/respcare.10132.

Understanding the Impact of Pulmonary Rehabilitation on Airway Resistance in Patients with Severe COPD: A Single-Center Retrospective Study.

Kilic L, Tural Onur S, Dilektasli A, Ulubay G, Balci A Int J Chron Obstruct Pulmon Dis. 2023; 18:1-10.

PMID: 36628301 PMC: 9826605. DOI: 10.2147/COPD.S384127.

References
1.
Littner M, Ilowite J, Tashkin D, Friedman M, Serby C, Menjoge S . Long-acting bronchodilation with once-daily dosing of tiotropium (Spiriva) in stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2000; 161(4 Pt 1):1136-42. DOI: 10.1164/ajrccm.161.4.9903044. View
2.
MAESEN F, Smeets J, Sledsens T, Wald F, CORNELISSEN P . Tiotropium bromide, a new long-acting antimuscarinic bronchodilator: a pharmacodynamic study in patients with chronic obstructive pulmonary disease (COPD). Dutch Study Group. Eur Respir J. 1995; 8(9):1506-13. View
3.
Goldman M . Clinical application of forced oscillation. Pulm Pharmacol Ther. 2001; 14(5):341-50. DOI: 10.1006/pupt.2001.0310. View
4.
Burns G, Gibson G . A novel hypothesis to explain the bronchconstrictor effect of deep inspiration in asthma. Thorax. 2002; 57(2):116-9. PMC: 1746262. DOI: 10.1136/thorax.57.2.116. View
5.
Vincken W, van Noord J, Greefhorst A, Bantje T, Kesten S, Korducki L . Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium. Eur Respir J. 2002; 19(2):209-16. DOI: 10.1183/09031936.02.00238702. View